Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 58, showing 10 Applications out of 576 total, starting on record 231, ending on 240

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

231.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
04-05-2022 View

232.

ECCT/22/03/07   ELEVATUM
    A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA   
Principal Investigator(s)
1. Dr. Oscar Muwale Onyango
2. Dr. Muchai Gachago
Site(s) in Kenya
1. The Nairobi Hospital (Nairobi City county)
2. City Eye Hospital (Nairobi City county)
 
05-09-2022 View

233.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
27-05-2022 View

234.

ECCT/22/03/02   MOVe AHEAD STUDY
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP KISUMU
 
31-05-2022 View

235.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
25-09-2022 View

236.

ECCT/22/02/02   The Women TAF-FTC Benchmark
    Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
18-11-2022 View

237.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
16-05-2022 View

238.

ECCT/22/05/03   Anti-malaria MAb in Kenyan chi
    Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya   
Principal Investigator(s)
1. Titus Kwambai
2. Laura Steinhardt
3. Robert A Seder
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Kogelo Health Center (Siaya county)
 
08-08-2022 View

239.

ECCT/22/01/02   CoVPN 3008
    Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern   
Principal Investigator(s)
1. Ben Madeke Andagalu
Site(s) in Kenya
1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
2. KEMRI-CGHR (Kisumu county)
 
14-04-2022 View

240.

ECCT/22/03/09   GBT 132-Inclacumub PH3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Videlis N Nduba
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. KEMRI/CRDR (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. Strathmore University Medical Centre (Nairobi City county)
 
30-05-2022 View